Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Adding to the flurry of gene-therapy deals, Pfizer has paid roughly $51 million for a 15% stake in Vivet Therapeutics, which is developing liver-directed gene therapies. Pfizer has an option to acquire the rest of Vivet after it unveils certain data on VTX-801, Vivet’s gene therapy for Wilson’s disease, which is caused by mutations in the gene encoding the ATP7B protein. So far in gene therapy this year, Biogen bought Nightstar Therapeutics, Roche acquired Spark Therapeutics, and Sarepta Therapeutics purchased Myonexus Therapeutics.
This article has been sent to the following recipient: